Table 1 Baseline characteristics of patients with COPD referred for rehabilitation
From: Vitamin D supplementation during rehabilitation in COPD: a secondary analysis of a randomized trial
| Placebo | Vitamin D | P-value | |||
|---|---|---|---|---|---|
| (n = 25) | (n = 25) | ||||
| Antropometric data: | |||||
| Age (years) | 69±6 | 67±8 | 0.464 | ||
| Gender (male/female) | 19/6 | 19/6 | 1.000 | ||
| BMI (kg/m2) | 24±6 | 25±5 | 0.587 | ||
| GOLD Stages | 0.492 | ||||
| I (n) | 0 | 2 | |||
| II (n) | 6 | 7 | |||
| III (n) | 15 | 12 | |||
| IV (n) | 4 | 4 | |||
| Serum vitamin D level: | |||||
| 25-OHD (ng/ml) | 20±11 | 23±15 | 0.492 | ||
| Pulmonary function: | |||||
| FEV1(l) | 1.06±0.28 | 40±10(*) | 1.22±0.50 | 47±18(*) | 0.115 |
| FVC (l) | 2.85±0.80 | 83±20(*) | 2.96±0.76 | 89±22(*) | 0.328 |
| Muscle function: | |||||
| QF (Nm) | 106±36 | 83±27(*) | 109±41 | 75±20(*) | 0.242 |
| MIP (cmH2O) | −77±26 | 72±20(*) | −67±24 | 63±21(*) | 0.107 |
| MEP (cmH2O) | 158±55 | 83±22(*) | 152±50 | 80±26(*) | 0.685 |
| Exercise Performance: | |||||
| 6MWD (meter) | 422±109 | 70±19(*) | 391±135 | 65±23(*) | 0.435 |
| VO2max (l/min) | 1.21±0.48 | 72±24(*) | 1.15±0.43 | 75±38(*) | 0.802 |
| Wmax (watt) | 71±27 | 54±22(*) | 67±29 | 52±25(*) | 0.713 |
| Health-Related Quality of Life: | |||||
| CRDQdyspnea (points) | 16.1±4.36 | 17.3±4.6 | 0.366 | ||
| CRDQtotal (points) | 82.6±16.0 | 83.1±17.4 | 0.721 | ||